NO20043953L - TRPM-2-antisenseterapi som anvender et antinukleotid med 2`-O-(2-metoksyl)etyl-modifiseringer - Google Patents
TRPM-2-antisenseterapi som anvender et antinukleotid med 2`-O-(2-metoksyl)etyl-modifiseringerInfo
- Publication number
- NO20043953L NO20043953L NO20043953A NO20043953A NO20043953L NO 20043953 L NO20043953 L NO 20043953L NO 20043953 A NO20043953 A NO 20043953A NO 20043953 A NO20043953 A NO 20043953A NO 20043953 L NO20043953 L NO 20043953L
- Authority
- NO
- Norway
- Prior art keywords
- antinucleotide
- trpm
- methoxyl
- antisense therapy
- ethyl modifications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/080,794 US6900187B2 (en) | 1999-02-26 | 2002-02-22 | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
PCT/US2003/005305 WO2003072591A1 (en) | 2002-02-22 | 2003-02-20 | Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20043953L true NO20043953L (no) | 2004-11-19 |
Family
ID=27765243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20043953A NO20043953L (no) | 2002-02-22 | 2004-09-21 | TRPM-2-antisenseterapi som anvender et antinukleotid med 2`-O-(2-metoksyl)etyl-modifiseringer |
Country Status (10)
Country | Link |
---|---|
US (1) | US6900187B2 (no) |
EP (1) | EP1485401A4 (no) |
JP (1) | JP2005530486A (no) |
KR (1) | KR20040088514A (no) |
AU (1) | AU2003213190A1 (no) |
CA (1) | CA2475433A1 (no) |
HU (1) | HUP0500041A3 (no) |
NO (1) | NO20043953L (no) |
NZ (1) | NZ534490A (no) |
WO (1) | WO2003072591A1 (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
HU229452B1 (en) * | 2002-01-17 | 2013-12-30 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
DK1530636T3 (da) * | 2002-08-21 | 2010-11-29 | Univ British Columbia | Behandling af melanomer ved reduktion af clusterinniveauet |
US20070021361A1 (en) * | 2002-12-04 | 2007-01-25 | Shuster Samuel J | Methods and materials for modulating trpm2 |
US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
WO2005094899A1 (en) * | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
CA2580504C (en) * | 2004-09-17 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
AU2005309274B2 (en) * | 2004-11-23 | 2011-07-21 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels |
ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
EP1941040A1 (en) * | 2005-09-19 | 2008-07-09 | Johnson & Johnson Pharmaceutical Research & Development L.L.C. | Modulation of glucocorticoid receptor expression |
JP5623016B2 (ja) * | 2005-12-01 | 2014-11-12 | プロネイ・セラピューティクス・インコーポレイテッドPronaitherapeutics, Inc. | 癌治療法およびそれに用いる医薬組成物 |
ES2419106T3 (es) | 2005-12-01 | 2013-08-19 | Pronai Therapeutics, Inc. | Formulación de liposomas anfóteros |
EP2300019A4 (en) * | 2008-07-18 | 2012-08-29 | Oncogenex Technologies Inc | Antisense FORMULATION |
CN102159247A (zh) * | 2008-07-30 | 2011-08-17 | 日东电工株式会社 | 药物载体 |
WO2011005779A2 (en) | 2009-07-07 | 2011-01-13 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
ES2734886T3 (es) | 2009-11-24 | 2019-12-12 | Alethia Biotherapeutics Inc | Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral |
CA2830195A1 (en) * | 2011-03-15 | 2012-09-20 | Martin E. Gleave | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
CN104159611A (zh) | 2012-02-22 | 2014-11-19 | 阿莱斯亚生物疗法股份有限公司 | 共使用簇集蛋白抑制剂和egfr抑制剂以治疗癌症 |
NZ700561A (en) * | 2012-04-23 | 2016-07-29 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
UY34812A (es) * | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
US10024844B2 (en) | 2012-12-20 | 2018-07-17 | Hospital For Special Surgery | Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2 |
ES2894333T3 (es) | 2013-09-26 | 2022-02-14 | Beth Israel Deaconess Medical Ct Inc | Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
JPH11143729A (ja) * | 1997-11-07 | 1999-05-28 | Nec Corp | フォールトトレラントコンピュータ |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
EP1242050A4 (en) | 1999-12-21 | 2004-05-26 | Univ Yale | STIMULATION OF ANGIOGEN SE BY THE USE OF SURVIVIN |
US20020132350A1 (en) | 2000-09-14 | 2002-09-19 | Pioneer Hi-Bred International, Inc. | Targeted genetic manipulation using Mu bacteriophage cleaved donor complex |
HU229452B1 (en) | 2002-01-17 | 2013-12-30 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
-
2002
- 2002-02-22 US US10/080,794 patent/US6900187B2/en not_active Expired - Fee Related
-
2003
- 2003-02-20 AU AU2003213190A patent/AU2003213190A1/en not_active Abandoned
- 2003-02-20 JP JP2003571297A patent/JP2005530486A/ja not_active Abandoned
- 2003-02-20 HU HU0500041A patent/HUP0500041A3/hu unknown
- 2003-02-20 KR KR10-2004-7013102A patent/KR20040088514A/ko not_active Application Discontinuation
- 2003-02-20 WO PCT/US2003/005305 patent/WO2003072591A1/en active Application Filing
- 2003-02-20 CA CA002475433A patent/CA2475433A1/en not_active Abandoned
- 2003-02-20 NZ NZ534490A patent/NZ534490A/en unknown
- 2003-02-20 EP EP03709236A patent/EP1485401A4/en not_active Withdrawn
-
2004
- 2004-09-21 NO NO20043953A patent/NO20043953L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20040088514A (ko) | 2004-10-16 |
NZ534490A (en) | 2006-05-26 |
JP2005530486A (ja) | 2005-10-13 |
EP1485401A4 (en) | 2007-08-01 |
HUP0500041A3 (en) | 2008-09-29 |
US6900187B2 (en) | 2005-05-31 |
HUP0500041A2 (hu) | 2005-03-29 |
EP1485401A1 (en) | 2004-12-15 |
AU2003213190A1 (en) | 2003-09-09 |
WO2003072591A1 (en) | 2003-09-04 |
CA2475433A1 (en) | 2003-09-04 |
US20030166591A1 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20043953L (no) | TRPM-2-antisenseterapi som anvender et antinukleotid med 2`-O-(2-metoksyl)etyl-modifiseringer | |
DE60217294D1 (de) | Hauteinschnittblutentnahmegerät | |
BRPI0313399A2 (pt) | terapia de troca de plasma seletiva | |
GB0206876D0 (en) | Therapeutic agents | |
GB0209991D0 (en) | Therapeutic agents | |
GB0209997D0 (en) | Therapeutic agents | |
GB0209995D0 (en) | Therapeutic agents | |
GB0210127D0 (en) | Therapeutic agents | |
DE60033715D1 (de) | Servo-Regler | |
GB0210124D0 (en) | Therapeutic agents | |
EP1490074A4 (en) | MIXED CELL GENE THERAPY | |
ATE329502T1 (de) | Fixiereinlage | |
GB0219660D0 (en) | Therapeutic use | |
DK1176982T3 (da) | Prucaloprid oral opløsning | |
GB0207595D0 (en) | Patient support structures | |
DZ3364A1 (fr) | Agent therapeutique cristallin | |
GB0217068D0 (en) | Therapeutic agents | |
AU2003243360A8 (en) | Polyamine-mediated transfection | |
GB0208394D0 (en) | Therapeutic agents | |
AU2003243605A8 (en) | 3-'2-(dimethylamino) ethyl | |
GB0212821D0 (en) | Eyewash | |
GB0213383D0 (en) | Therapeutic conditions | |
NO20014850D0 (no) | CML-terapi | |
UA4395S (uk) | Тренажер для м`язів спини | |
GB0210435D0 (en) | Weeders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |